An Analysis of Remdesivir Patenting

Tingbin CHANG, Zhong WANG

Abstract


Pharmaceutical patents are categorized into primary patents and secondary patents. Primary patents refer to compound patents, while secondary patents mainly include crystalline form patents, process patent, formulation patent and method of use patent. In the recent outbreak of COVID-19, Wuhan Institute of Virology, has applied for a new method of use patent on Remdesivir for its efficacy and safety in the treatment of the pneumonia caused by 2019-nCoV. But Gilead Sciences, the inventor of Remdesivir, is the eligible holder of the compound patent of Remdesivir. In theory, the patent applied for by Wuhan Institute of Virology has utility and novelty rather than innovativeness, for which it may not be granted the method of use patent of Remdesivir. In this case, we suggest that the patent of Remdesivir be implemented through cross licensing and compulsory licensing between different patent holders.


Keywords


Remdesivir; Pharmaceutical patents; Compulsory licensing

Full Text:

PDF

References


Hu, X. H., & Xu, J. (2005). On the legitimacy and the principles of restrictions on the basic rights of citizens. Law Review, (6).

Huang, L., Qian, L., etc. (2017). Patent Protection and Patent Strategy in Pharmaceutical Industry. Chinese Journal of New Drugs, (2).

Liu, C. Q. (2020). Chinese research institute’s patent application is not a bad-faith infringement. Retrieved 26th Feburary 2020 from https://www.yicai.com/news/100491185.html.

Liu, C. T. (2014). Intellectual property law. China Renmin University Press.

Wang, M. L., Cao, R. Y., Zhang, L. K., et al. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Retrieved 20th Feburary 2020 from https://www.nature.com/articles/s41422-020-0282-0.

Wu, H. D. (2003). Intellectual property law. Law Press·China.

Xiao, X. X. (2012). New chemical entity drug patent layout strategy – A case study of AstraZeneca’s patents on Gefitinib in China. China Invention & Patent, (1).

Xiong, W. C. (2020). An analysis of the remdesivir method of use patent filed by Wuhan institute of virology. Retrieved 26th Feburary 2020 from https://mp.weixin.qq.com/s/m6r67Z8lJ6rFsixE9vH0TA.

Yao, L. (2012). Is “Off-Label Drug Use” A medical infringement?. Medicine Economics Report, (5).

Zhang, H., Ma, Q. J., etc. (2016). Discussion on the Novelty of Patents on the Crystalline Form of Drugs. Chinese Journal of New Drug, (5).

Zhang, P. (2012). Principles and practices of patent authorization and confirmation system. Intellectual Property Publishing House.




DOI: http://dx.doi.org/10.3968/11863

Refbacks

  • There are currently no refbacks.


Copyright (c) 2020 Tingbin CHANG

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Share us to:   

Remind

We are currently accepting submissions via email only.

The registration and online submission functions have been disabled.

Please send your manuscripts to ccc@cscanada.net，or  ccc@cscanada.org  for consideration. We look forward to receiving your work.

 

 Articles published in Cross-Cultural Communication are licensed under Creative Commons Attribution 4.0 (CC-BY).

 CROSS-CULTURAL COMMUNICATION Editorial Office

Address: 1055 Rue Lucien-L'Allier, Unit #772, Montreal, QC H3G 3C4, Canada.
Telephone: 1-514-558 6138 
Website: Http://www.cscanada.net; Http://www.cscanada.org 
E-mail:caooc@hotmail.com; office@cscanada.net

Copyright © Canadian Academy of Oriental and Occidental Culture